SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
Quarterly Report Under Section 13 or 15(d)
of the Securities Exchange Act of 1934
For the quarterly period ended November 30, 1999
Commission file number 000-25157
DR. ABRAVANEL'S FORMULAS, INC.
________________________________________________________________
(Exact name of small business issuer as specified in its charter)
Nevada 95-4685068
____________________________ ________________________________
(State or other jurisdiction of (IRS Employer Identification Number)
incorporation or organization
124 South Hudson Avenue
Los Angeles CA 90004
________________________________________
(Address of principal executive offices)
(213) 933-0163
________________________________________________
(Issuer's telephone number, including area code)
Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file
such reports) Yes [X] No [ ], and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
APPLICABLE ONLY TO CORPORATE ISSUERS:
State the number of shares outstanding of each of the issuer's classes of
common equity, as of the latest practicable date:
As of November 30, 1999, the issuer had outstanding 12,841,353 shares of
its Common Stock, $0.001 par value.
1
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
The unaudited financial statements of Dr. Abravanel's Formulas, Inc., a
Nevada corporation (the "Company"), as of November 30, 1999, were prepared by
Management and commence on the following page. In the opinion of Management
the financial statements fairly present the financial condition of the
Company.
Dr. Abravanel's Formulas, Inc.
(A Development Stage Company)
Financial Statements
For the Nine Month Period Ended November 30, 1999
2
<PAGE>
Dr. Abravanel's Formulas, Inc.
(A Development Stage Company
Balance Sheet
November 30, 1999
Assets
Current Assets
Cash $ 5,263
Inventory (note 1) 12,790
-------------
Total current assets 18,053
Note receivable 525
Deferred taxes, net (notes 1 and 4) 8,260
-------------
Total assets $ 26,838
=============
Liabilities and Shareholders' Equity
Shareholders' equity (note 3)
Common stock, $.001 par,
authorized 40,000,000 shares; 12,841,353
shares issued and outstanding $ 12,841
Additional paid-in capital- common stock 132,018
Special distribution (notes 2 and 5) (60,000)
Common stock offering costs (33,685)
Preferred stock, $.001 par, authorized 10,000,000
shares; 0 shares issued and outstanding -
Deficit accumulated during the development stage (24,336)
-------------
Total liabilities and shareholders' equity $ 26,838
=============
See accompanying notes to financial statements.
3
<PAGE>
Dr. Abravanel's Formulas, Inc.
(A Development Stage Company)
Statement of Operations
For the Nine Month Period Ended November 30, 1999
and the Period from Inception (April 28, 1998) to November 30, 1999
Nine Month Period from Inception
Period Ended (April 28, 1998) to
November 30, 1999 November 30, 1999
--------------- ---------------------
Sales $ - $ -
Cost of sales - -
--------------- ---------------------
Gross profit - -
--------------- ---------------------
Costs and expenses:
General administrative 5,882 32,596
--------------- ---------------------
Total costs and expenses 5,882 32,596
--------------- ---------------------
Net loss before income taxes (5,882) (32,596)
Income tax benefit attributable to
continuing operations (note 4) 2,650 8,260
--------------- ---------------------
Net income (loss) $ (3,232) $ (24,336)
=============== =====================
Net loss before income taxes per share
(note 1) $ (0.01) $ (0.01)
Net loss per share (note 1) $ (0.01) $ (0.01)
Weighted average common shares
(in thousands) (note 1) 12,841 12,309
=============== =====================
See accompanying notes to financial statements.
4
<PAGE>
Dr. Abravanel's Formulas, Inc.
(A Development Stage Company)
Statement of Shareholders' Equity
For the Nine Month Period Ended November 30, 1999
and the Period from Inception (April 28, 1998) to November 30, 1999
Nine Month Period from Inception
Period Ended (April 28, 1998) to
November 30, 1999 November 30, 1999
------------------ ---------------------
Beginning balance 62,107 -
Issuance of common stock:
10,000,000 shares on 4/28/98 (issued as
partial consideration for product
formulas; valued at stock par value) 10,000
25,000 shares on 6/15/98 250
53,500 shares on 6/15/98 8,025
100,000 shares on 7/10/98 15,000
10,000 shares on 7/16/98 100
40,000 shares on 7/16/98 6,000
135,000 shares on 7/23/98 1,350
233,461 shares on 7/23/98 35,019
27,500 shares on 7/30/98 275
33,500 shares on 7/30/98 5,025
25,000 shares on 8/18/98 250
81,667 shares on 8/18/98 12,250
750,000 shares on 8/20/98 750
60,600 shares on 8/21/98 9,090
100,000 shares on 8/21/98 1,000
137,500 shares on 8/25/98 1,375
173,000 shares on 8/25/98 25,950
750,000 shares on 8/26/98 750
40,000 shares on 8/31/98 400
10,000 shares on 9/04/98 1,500
55,625 shares on 9/18/98 10,500
Special distribution (19,475) (60,000)
Common stock offering costs (12,562) (33,685)
Net loss (3,232) (24,336)
--------------- ---------------------
Balance at November 30, 1999 26,838 26,838
=============== =====================
See accompanying notes to financial statements.
5
<PAGE>
Dr. Abravanel's Formulas, Inc.
(A Development Stage Company)
Statement of Cash Flows
For the Nine Month Period Ended November 30, 1999
and the Period from Inception (April 28, 1998) to November 30, 1999
Nine Month Period from Inception
Period Ended (April 28, 1998) to
November 30, 1999 November 30, 1999
------------------ ---------------------
Cash flow from operating activities
Net loss $ (3,232) $ (24,336)
Adjustments to reconcile net income to net
cash used in operating activities:
Increase in deferred taxes (2,650) (8,260)
Changes in assets and liabilities:
Inventory (12,790)
--------------- ---------------------
Net cash used by operations (5,882) (45,386)
Cash flows from financing activities
Note receivable (525) (525)
Issuance of common stock 134,859
Common stock offering costs (12,562) (33,685)
Payment of special distribution (19,475) (50,000)
--------------- ---------------------
Net increase (decrease) in cash (38,444) 5,263
Cash at beginning of period 43,707 -
--------------- ---------------------
Cash at end of period $ 5,263 $ 5,263
=============== ====================
See accompanying notes to financial statements.
6
<PAGE>
Dr. Abravanel's Formulas, Inc.
(A Development Stage Company)
Statement of Cash Flows
For the Nine Month Period Ended November 30, 1999
and the Period from Inception (April 28, 1998) to November 30, 1999
Nine Month Period from Inception
Period Ended (April 28, 1998) to
November 30, 1999 November 30, 1999
------------------ ---------------------
Supplemental cash flow disclosures:
Interest paid $ - $ -
=============== ====================
Income taxes paid $ - $ -
=============== ====================
Non cash transactions:
On April 28, 1998, 10,000,000 shares of common stock were issued as
payment for product formulas valued at $10,000.
See accompanying notes to financial statements.
7
<PAGE>
Dr. Abravanel's Formulas, Inc.
(A Development Stage Company)
Notes to the Financial Statements
For the Nine Month Period Ended November 30, 1999
Note 1 - Nature of business and summary of significant accounting policies
Nature of business - Dr. Abravanel's Formulas, Inc. was incorporated on April
28, 1998 in the state of Nevada. The Company was formed as a nutritional
supplement development and marketing corporation. The Company has developed
products specifically for the reduction or elimination of cravings in people.
As a development stage company, management's efforts have been in product
development and marketing strategies.
Basis of presentation - The financial statements have been prepared in
conformity with generally accepted accounting principals.
Inventories - Inventories, which at November 30, 1999, consisted primarily of
production supplies, are stated at the lower of cost or market determined on
the first-in, first-out (FIFO) basis.
Intangibles - Start-up costs, research and development costs and formula costs
are charged to expense in the period incurred.
Income taxes - The Company accounts for income taxes under the provisions of
SFAS No. 109, Accounting for Income Taxes (SFAS No. 109). Under the asset and
liability method of SFAS No. 109, deferred tax assets and liabilities are
recognized for the future tax consequences attributable to differences between
the financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are
measured using enacted tax rates expected to apply to taxable income in the
years in which those temporary differences are expected to be recovered or
settled. Under SFAS No. 109, the effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period
that includes the enactment date.
Estimates - The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities at
the date of the financial statements and the reported amounts of revenue and
expenses during the reporting period. Actual amounts could differ from those
estimates.
Per share information - Per share information has been computed using the
weighted average number of common shares outstanding during the period.
Note 2 - Contract payable
Effective on April 28, 1998, the Company entered into an agreement to purchase
specific existing nutritional formulations as well as the non-exclusive use of
formulas to be developed in the future.
In exchange for the formulas, the Company agreed to give 10,000,000 shares of
common stock, with a par value of $10,000, and $50,000 in cash. The stock was
issued on April 28, 1998, and the cash was paid in installments of $30,525 in
1998, and $19,475 in March, 1999.
8
<PAGE>
Note 3 - Shareholders' equity
Voting rights and powers - Common stock shall be entitled to cast thereon one
(1) vote in person or by proxy for each share of the common stock standing in
his name.
Dividends and distributions -
a) Cash dividends - subject to the rights of holders of preferred
stock, holders of common stock shall be entitled to receive such cash
dividends as may be declared thereon by the board of directors from time to
time out of assets or funds of the Corporation legally available therefor;
b) Other dividends and distributions - The board of directors may
issue shares of the common stock in the form of a distribution or
distributions pursuant to a stock dividend or split-up of the shares of the
common stock;
c) Other rights - Except as otherwise required by the Nevada Revised
Statutes and as may otherwise be provided in these Amended Articles of
Incorporation, each share of the common stock shall have identical powers,
preferences and rights, including rights in liquidation;
Preferred stock - The powers, preferences, rights, qualifications, terms,
limitations and restrictions pertaining to the preferred stock, or any series
thereof, shall be such as may be fixed, from time to time, by the board of
directors in its sole discretion, authority to do so being hereby expressly
vested in the board.
Transfer restrictions - No sale, offer to sell, or transfer of any common
stock issued shall be made unless a registration statement under the Federal
Securities Act of 1933, as amended with respect to such shares is then in
effect or an exemption from the registration requirements of said act is then
in fact applicable to said shares. In addition, all common stock issued at
$.01 (500,000 shares) may not be sold, offered for sale, or transferred unless
approved and authorized in writing by the Company's board of directors.
Note 4 - Income taxes
As of November 30, 1999 the Company has available net operating loss
carryforwards of approximately $39,000. These carryforwards will expire in
the years 2014 and 2015. As of November 30, 1999, the Company recognized a
deferred tax asset amounting to $8,260 from its loss carryovers.
Total deferred tax assets from net operating
loss carryovers $ 8,260
Less valuation allowance -
-----------
Deferred tax assets, net $ 8,260
===========
Total deferred tax liabilities $ -
===========
9
<PAGE>
Deferred Valuation Deferred tax
tax assets allowance assets (net)
----------- ----------- ------------
Beginning balance $ 5,610 $ - $ 5,610
Current tax (expense) benefit 2,650 - 2,650
Current adjustment in valuation allowance - - -
----------- ----------- ------------
Balance at November 30, 1999 $ 8,260 $ 0 $ 8,260
=========== =========== ============
Statutory tax on pre-tax income from
continuing operations $ -
Deferred tax expense or (benefit) (2,650)
Current adjustment in valuation allowance -
----------
Income tax expense (benefit) attributable
to continuing operations $ (2,650)
==========
Note 5 - Related party transactions
On April 28, 1998, the Company purchased certain nutritional formulations from
Elliot D. Abravanel, MD and Mark Delott, the only officers and directors of
the Company for $50,000 and 10,000,000 shares of common stock.
Note 6 - Contingencies
The Company is dependent on Dr. Elliot Abravanel for the development and
marketing of the Company's product line.
Note 7 - Private placement memorandum and filings with the SEC
As of November 30, 1999, 1,341,353 shares of common stock have been issued
through the Company's private placement offerings. The Company has applied
for and received the CUSIP number for the or the Company's publically traded
shares. The Company, through its sponsoring market maker Equitrade
Securities, Inc., filed Form 211 on July 21, 1999, for listing its shares on
the OTC Electronic Bulletin Board. The Company has received two sets of
comments from the OTC Bulletin Board examiners and responded to them. The
Company filed with the SEC on December 30, 1998, and this filing became
effective As of September 30, 1999, the Company has received two sets of
comments from OTC Bulletin Board examiners and responded to them. The Company
filed with the SEC on December 10, 1998, and this filing became effective
February 8, 1999. The Company has been notified by the SEC
that all questions and comments have been cleared.
Note 8 - Subsequent events
The Company anticipates the need for additional capital to launch its product
line. Management may elect to sell additional equity, debt or enter into
partnerships to fund its financial needs. Currently, the Company has
developed its first product, "Replen 100 for Vibrant Health," and has a
limited inventory of this product.
10
<PAGE>
Item 2. Management's Discussion and Analysis of Financial Condition or
Plan of Operation
The following discussion provides information which Management believes
is relevant to an assessment and understanding of the Company's plan of
operation. This discussion should be read in conjunction with the Company's
financial statements and notes.
The Company, which incorporated in the State of Nevada on April 28, 1998,
primarily as a nutritional supplement development and marketing corporation,
has not yet commenced substantive operations. Since inception, the Company
raised approximately $133,000 through an offering of its common stock made
pursuant to the exemption from the registration requirements as provided for
under Section 3(b), Regulation D, Rule 504. It also issued 10,000,000 shares
to its founders, Mark Delott and Elliot Abravanel, M.D., pursuant to a
technology transfer agreement which granted the Company 100% of the rights to
existing formulas developed by Dr. Elliot Abravanel M.D., and non-exclusive
use of formulas to be developed in the future. The Company's business purpose
is that of marketing certain products developed by Dr. Abravanel specifically
for the reduction or elimination of cravings for sugar, starch and greasy
food, as well as supplements for general well being.
The Company has expended the majority of the funds raised in its offering
on purchase of the formulas, offering costs and general administrative
expenses since inception. The Company currently has approximately $ 5,263 in
cash to satisfy is cash requirements over the next 12 months, and $12,790
worth of inventory of its products, which will likely be insufficient unless
the Company continues to operate at its existing level, with minimal day to
day operations expenses, and little or no money dedicated to marketing.
In early 1999 the Company narrowed its initial product focus to three
products:
1. Dr. Abravanel's Special Formula for Weight Loss
2. Dr. Abravanel's Special Formula for Vibrant Health
3. Dr. Abravanel's Special Formula for Meal Replacement
During the its first fiscal quarter, the Company completed development
and limited production of one of the above three products: Dr. Abravanel's
Special Formula for Vibrant Health". The Company has named the product
"Replen 100 for Vibrant Health" ("Replen 100"). The Company has a limited
inventory of this product. Since the beginning of its first fiscal quarter,
the Company's efforts in marketing have mostly been conducted by Management
and limited to testing the market place in a limited manner as to market
acceptance of its product, Replen 100. During the first three quarters of its
current fiscal year, the Company randomly distributed free samples to a
variety of individuals and received input about the product's results from
these persons. During the Company's third quarter, Management determined,
based on its sampling, that further refinements of the Replen 100 are needed
since most of the test market subjects did not express an interest in ordering
the product. While the antecdotal results are somewhat favorable, the Company
must reevaluate the initial product, Replen 100, prior to resuming its test
marketing or prior to any substantive marketing campaign. In addition,
Management's analysis of the industry continues to indicate that profit
margins in the industry have radically declined. This could result in reduced
profit margins to the Company's products, if and when marketed, in order to
remain competitive. Management, therefore, has determined that while the
efficacy of Replen 100 is sound, the impact of the results of the test market
11
<PAGE>
subjects is not readily apparent. Going into the Company's fourth quarter,
Management intends to rethink and redevelop its product ingredients for Replen
100 which may include both adding or subtracting ingredients. There are no
plans for research and development of any other products at this time, nor
does the Company have any plans for purchase of property or equipment. The
Company does not have any lease payments or salaries to pay at this time.
All of Company's limited capital of $5,263 is dedicated to its
business plan as needed. General administrative expenses during the quarter
ended November 30, 1999, were approximately $6,200, and Management expects
such expenses to be less for the next quarter. The cash available to the
Company will be sufficient to cover general administrative expenses for 12
months so long as the Company does not incur any additional expenses in its
day to day operations or any expenses in connection with marketing. The
Company also has sufficient inventory if it decides to continue to provide
free samples and solicit product interest as well as anecdotal evidence to
determine Replen 100's effectiveness and market acceptance.
Management believes it has sufficient funds to cover basic administrative
costs over the next 12 months. However, because the Company intends to
reevaluate its Replen 100, it will likely require additional capital to do so.
Such capital may be raised through private placements of its common equity,
debt financing, bank loans, or through licensing or joint ventures with other
companies. There are no current commitments for financing, and there is no
assurance that such financing will be available when needed, or that if the
Company succeeds in raising additional funds, that the same will be sufficient
for its business purposes. During the fourth quarter, Management will seek
capital from a variety of sources including investment bankers and private
investors, as well as potential joint venture partners. The Company may be
forced to redefine its business goals in order to maximize shareholder value
in the event further capital cannot be easily obtained.
YEAR 2000
The Company is currently addressing a universal situation know as the
Year 2000 problem or the Y2K problem. The Y2K problem relates to the
inability of certain computer software programs to properly recognize and
process date-sensitive information relative to year 2000 and beyond. The
Company's internal computer operating system is Y2K compliant as is all
software currently utilized by the Company. The Company does not intend to
add any software to its operating system without making sure that it is Y2K
compliant.
Because, as is the case with almost all companies, the Company's Y2K
compliance is in part dependent upon certain of its suppliers and vendors
being Y2K compliant, the Company intends to communicate with all of its
suppliers/vendors to determine whether not they are Y2K compliant. If they
are not, the Company will seek other suppliers/vendors which are. Because
there are a vast number of suppliers which can provide the ingredients for the
Company's products, and who can process and out-source orders, the Company
does not anticipate having a Y2K problem getting ingredients or distributing
its products. In the event the Company is forced to use alternative suppliers
for its ingredients, the Company believes it will be able to negotiate the
same or similar terms and costs. The Company also believes the same will be
true with its vendors. Because of the availability of numerous vendors/
suppliers, the Company does not believe it will incur any additional expenses
due to Y2K problems. The Company does not, therefore, have any Y2K
contingency plans, with respect to obtaining ingredients from suppliers, or
12
<PAGE>
alternative distributors.
ANY FORWARD-LOOKING STATEMENTS INCLUDED IN THIS FORM 10-QSB REFLECT
MANAGEMENT'S BEST JUDGMENT BASED ON FACTORS CURRENTLY KNOWN AND INVOLVE RISKS
AND UNCERTAINTIES. ACTUAL RESULTS MAY VARY MATERIALLY.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
None
Item 2. Changes in Securities
None.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Submission of Matters to a Vote of Security Holders
None.
Item 5. Other Information.
None.
Item 6. Exhibits and Reports on Form 8-K.
(a)There are no exhibits included with this report.
Exhibit 27 - Financial Data Schedule
(b) Reports on Form 8-K -- None
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of
1934, the Registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
DR ABRAVANEL'S FORMULAS
(Registrant)
Date: December 16, 1999 By: /s/ Elliot Abranvanel
------------------------
Elliot Abravanel, MD
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 9-MOS
<FISCAL-YEAR-END> FEB-28-2000
<PERIOD-END> NOV-30-1999
<CASH> 5,263
<SECURITIES> 0
<RECEIVABLES> 525
<ALLOWANCES> 0
<INVENTORY> 12,790
<CURRENT-ASSETS> 18,053
<PP&E> 0
<DEPRECIATION> 0
<TOTAL-ASSETS> 26,838
<CURRENT-LIABILITIES> 0
<BONDS> 0
0
0
<COMMON> 12,841
<OTHER-SE> 13,997
<TOTAL-LIABILITY-AND-EQUITY> 26,838
<SALES> 0
<TOTAL-REVENUES> 0
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 5,882
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (5,882)
<INCOME-TAX> 2,650
<INCOME-CONTINUING> (3,232)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (3,232)
<EPS-BASIC> (0.01)
<EPS-DILUTED> (0.01)
</TABLE>
